

Vaxart Presented at the Modern Vaccines Adjuvants & Delivery Systems MVADS 2015

SOUTH SAN FRANCISCO, Calif., May 18 -- (BUSINESS WIRE) -- Vaxart, a privately held, clinical-stage company developing recombinant vaccines that are administered by tablet rather than by injection, today announced that Vaxart founder and chief scientific officer Sean Tucker, PhD, presented pre-clinical data from its Ebola vaccine program at the Modern Vaccines Adjuvants & Delivery Systems MVADS 2015 in Leiden, NL.

Dr. Tucker discussed the data in his presentation, "*Clinical development of an oral vaccine to prevent Ebola virus infection*," on Monday, May 18, 2015.

About Vaxart

Vaxart is a privately held, clinical-stage company developing tablet vaccines. The company's proprietary delivery platform is suitable to deliver any recombinant vaccine in oral form and allows rapid development to address emerging threats. Vaxart vaccines can be conveniently self-administered, with no cold chain distribution requirements and no medical waste. For more information, please visit www.vaxart.com.

CONTACT:

Katie Hogan

WCG

415.658.9745

khogan@wcgworld.com